{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:45:32Z","timestamp":1791377132410,"version":"4.3.2"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12035-023-03671-7","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T06:01:50Z","timestamp":1697176910000},"page":"1969-1989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"61","author":[{"given":"Unnati","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Johari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5505-2719","authenticated-orcid":false,"given":"Priyanka","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"3671_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/539179a","volume":"539","author":"M-T Heemels","year":"2016","unstructured":"Heemels M-T (2016) Neurodegenerative diseases. Nature 539:179\u2013179. https:\/\/doi.org\/10.1038\/539179a","journal-title":"Nature"},{"key":"3671_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM et al (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7:47. https:\/\/doi.org\/10.1038\/s41572-021-00280-3","journal-title":"Nat Rev Dis Primers"},{"key":"3671_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"OW Francis","year":"2007","unstructured":"Francis OW (2007) Huntington\u2019s disease. The Lancet 369:218\u2013228. https:\/\/doi.org\/10.1016\/S0140-6736(07)60111-1","journal-title":"The Lancet"},{"key":"3671_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3410\/f.726951684.793548675","volume":"539","author":"A Budson","year":"2018","unstructured":"Budson A, Jason W (2018) Faculty opinions recommendation of the road to restoring neural circuits for the treatment of Alzheimer\u2019s disease. Nature 539:187\u2013196. https:\/\/doi.org\/10.3410\/f.726951684.793548675","journal-title":"Nature"},{"issue":"2","key":"3671_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","volume":"119","author":"MG Savelieff","year":"2019","unstructured":"Savelieff MG, Nam G, Kang J et al (2019) Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev 119(2):1221\u20131322. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00138","journal-title":"Chem Rev"},{"key":"3671_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41583-018-0113-1","volume":"20","author":"CM Henstridge","year":"2019","unstructured":"Henstridge CM, Hyman BT, Spires-Jones TL (2019) Beyond the neuron\u2013cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci 20:94\u2013108. https:\/\/doi.org\/10.1038\/s41583-018-0113-1","journal-title":"Nat Rev Neurosci"},{"key":"3671_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.arr.2016.01.002","volume":"30","author":"L Pini","year":"2016","unstructured":"Pini L, Pievani M, Bocchetta M et al (2016) Brain atrophy in Alzheimer\u2019s disease and aging. Ageing Res Rev 30:25\u201348. https:\/\/doi.org\/10.1016\/j.arr.2016.01.002","journal-title":"Ageing Res Rev"},{"key":"3671_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fnbeh.2015.00347","volume":"9","author":"JV Sanchez-Mut","year":"2015","unstructured":"Sanchez-Mut JV, Gr\u00e4ff J (2015) Epigenetic alterations in Alzheimer\u2019s disease. Front Behav Neurosci 9:347. https:\/\/doi.org\/10.3389\/fnbeh.2015.00347","journal-title":"Front Behav Neurosci"},{"issue":"3","key":"3671_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3233\/JAD-2010-100012","volume":"20","author":"CM Carlsson","year":"2010","unstructured":"Carlsson CM (2010) Type 2 diabetes mellitus, dyslipidemia, and Alzheimer\u2019s disease. JAD 20(3):711\u2013722. https:\/\/doi.org\/10.3233\/JAD-2010-100012","journal-title":"JAD"},{"key":"3671_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M et al (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15:565\u2013581. https:\/\/doi.org\/10.1038\/s41582-019-0244-7","journal-title":"Nat Rev Neurol"},{"key":"3671_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ijbiomac.2020.07.327","volume":"163","author":"S Muralidar","year":"2020","unstructured":"Muralidar S, Ambi SV, Sekaran S et al (2020) Role of tau protein in Alzheimer\u2019s disease: the prime pathological player. Int J Biol Macromol 163:1599\u20131617. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.07.327","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"3671_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/ijms20020381","volume":"20","author":"KH Wong","year":"2019","unstructured":"Wong KH, Riaz MK, Xie Y et al (2019) Review of current strategies for delivering Alzheimer\u2019s disease drugs across the blood-brain barrier. Int J Mol Sci 20(2):381. https:\/\/doi.org\/10.3390\/ijms20020381","journal-title":"Int J Mol Sci"},{"key":"3671_CR13","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1126\/science.1566067","volume":"256","author":"J Hardy","year":"1992","unstructured":"Hardy J, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:5054. https:\/\/doi.org\/10.1126\/science.1566067","journal-title":"Science"},{"key":"3671_CR14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/bkcs.12390","volume":"42","author":"H Choi","year":"2021","unstructured":"Choi H, Kim E, Choi JY et al (2021) Potent therapeutic targets for treatment of Alzheimer\u2019s disease: amyloid degrading enzymes. Korean Chem Soc 42:1419\u20131429. https:\/\/doi.org\/10.1002\/bkcs.12390","journal-title":"Korean Chem Soc"},{"key":"3671_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","volume":"4","author":"PP Liu","year":"2019","unstructured":"Liu PP, Xie Y, Meng XY et al (2019) History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease. Sig Transduct Target Ther 4:29. https:\/\/doi.org\/10.1038\/s41392-019-0063-8","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"3671_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756285612461679","volume":"6","author":"KG Yiannopoulou","year":"2013","unstructured":"Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disord 6(1):19\u201333. https:\/\/doi.org\/10.1177\/1756285612461679","journal-title":"Ther Adv Neurol Disord"},{"key":"3671_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","volume":"245","author":"MM Wen","year":"2014","unstructured":"Wen MM, El-Salamauni NS, Refaie WM et al (2014) Nanotechnology-based drug delivery systems for Alzheimer\u2019s disease management: technical, industrial, and clinical challenges. J Control Release 245:95\u2013107. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.025","journal-title":"J Control Release"},{"key":"3671_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"M Agrawal","year":"2018","unstructured":"Agrawal M, Saraf S, Saraf S et al (2018) Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 281:139\u2013177. https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.011","journal-title":"J Control Release"},{"key":"3671_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12951-021-00864-x","volume":"19","author":"A Cano","year":"2021","unstructured":"Cano A, Turowski P, Ettcheto M et al (2021) Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer\u2019s disease: from current to future challenges. J Nanobiotechnol 19:122. https:\/\/doi.org\/10.1186\/s12951-021-00864-x","journal-title":"J Nanobiotechnol"},{"key":"3671_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"N Abbott","year":"2006","unstructured":"Abbott N, R\u00f6nnb\u00e4ck L, Hansson E (2006) Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier. Nat Rev Neurosci 7:41\u201353. https:\/\/doi.org\/10.1038\/nrn1824","journal-title":"Nat Rev Neurosci"},{"issue":"32","key":"3671_CR21","doi-asserted-by":"publisher","first-page":"9141","DOI":"10.1073\/pnas.2002016117","volume":"117","author":"D Gonzalez-Carter","year":"2020","unstructured":"Gonzalez-Carter D, Liu X, Tockary TA et al (2020) Targeting nanoparticles to the brain by exploiting the blood\u2013brain barrier impermeability to selectively label the brain endothelium. Proc Natl Acad Sci 117(32):9141\u201319150. https:\/\/doi.org\/10.1073\/pnas.2002016117","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"3671_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","volume":"83","author":"L Zhang","year":"2008","unstructured":"Zhang L, Gu FX, Chan JM et al (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83(5):761\u2013769. https:\/\/doi.org\/10.1038\/sj.clpt.6100400","journal-title":"Clin Pharmacol Ther"},{"key":"3671_CR23","doi-asserted-by":"publisher","first-page":"969547","DOI":"10.3389\/fcell.2022.969547","volume":"10","author":"G Pfundstein","year":"2022","unstructured":"Pfundstein G, Nikonenko AG, Sytnyk V (2022) Amyloid precursor protein (APP) and amyloid \u03b2 (A\u03b2) interact with cell adhesion molecules: implications in Alzheimer\u2019s disease and normal physiology. Front Cell Dev Biol 10:969547. https:\/\/doi.org\/10.3389\/fcell.2022.969547","journal-title":"Front Cell Dev Biol"},{"key":"3671_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/9781119711698.ch8","volume":"8","author":"RN Wadetwar","year":"2021","unstructured":"Wadetwar RN, Godbole AP (2021) Nanocarriers: a tool for effective gene delivery. Nanopharmaceutical Adv Deliv Syst 8:161\u2013185. https:\/\/doi.org\/10.1002\/9781119711698.ch8","journal-title":"Nanopharmaceutical Adv Deliv Syst"},{"issue":"14","key":"3671_CR25","doi-asserted-by":"publisher","first-page":"2100540","DOI":"10.1002\/advs.202100540","volume":"8","author":"C Yu","year":"2021","unstructured":"Yu C, Li L, Hu P et al (2021) Recent advances in stimulus-responsive nanocarriers for gene therapy. Adv Sci 8(14):2100540. https:\/\/doi.org\/10.1002\/advs.202100540","journal-title":"Adv Sci"},{"issue":"1","key":"3671_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1176\/jnp.7.1.54","volume":"7","author":"RS Doody","year":"1995","unstructured":"Doody RS, Massman P, Mahurin R et al (1995) Positive and negative neuropsychiatric features in Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci 7(1):54\u201360. https:\/\/doi.org\/10.1176\/jnp.7.1.54","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"3671_CR27","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-180098","volume":"63","author":"Z Cai","year":"2018","unstructured":"Cai Z, Qiao PF, Wan CQ et al (2018) Role of blood-brain barrier in Alzheimer\u2019s disease. J Alzheimers Dis 63(4):1223\u20131234. https:\/\/doi.org\/10.3233\/JAD-180098","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"3671_CR28","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"2","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K et al (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 2(10):5481\u20135503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0","journal-title":"Mol Psychiatry"},{"key":"3671_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijbiomac.2020.11.192","volume":"167","author":"H Ashrafian","year":"2021","unstructured":"Ashrafian H, Zadeh EH, Khan RH (2021) Review on Alzheimer\u2019s disease: inhibition of amyloid beta and tau tangle formation. Int J Biol\\ Macromol 167:382\u2013394. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.11.192","journal-title":"Int J Biol\\ Macromol"},{"issue":"33","key":"3671_CR30","doi-asserted-by":"publisher","first-page":"11159","DOI":"10.1523\/JNEUROSCI.0180-14.2014","volume":"34","author":"F Baumk\u00f6tter","year":"2014","unstructured":"Baumk\u00f6tter F, Schmidt N, Vargas C et al (2014) Amyloid precursor protein dimerization and synaptogenic function depend on copper binding to the growth factor-like domain. J Neurosci 34(33):11159\u201311172. https:\/\/doi.org\/10.1523\/JNEUROSCI.0180-14.2014","journal-title":"J Neurosci"},{"key":"3671_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00249-007-0234-3","volume":"37","author":"GKW Kong","year":"2008","unstructured":"Kong GKW, Miles LA, Crespi GAN et al (2008) Copper binding to the Alzheimer\u2019s disease amyloid precursor protein. Eur Biophys J 37:269\u2013279. https:\/\/doi.org\/10.1007\/s00249-007-0234-3","journal-title":"Eur Biophys J"},{"key":"3671_CR32","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/brain\/awl251","volume":"129","author":"LM Colin","year":"2006","unstructured":"Colin LM, Beyreuther K (2006) Alzheimer\u2019s centennial legacy: prospects for rational therapeutic intervention targeting the A\u03b2 amyloid pathway. Brain 129:2823\u20132839. https:\/\/doi.org\/10.1093\/brain\/awl251","journal-title":"Brain"},{"key":"3671_CR33","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y et al (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38:1205\u20131235. https:\/\/doi.org\/10.1038\/aps.2017.28","journal-title":"Acta Pharmacol Sin"},{"key":"3671_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4155\/fso.15.9","volume":"1","author":"R MacLeod","year":"2015","unstructured":"MacLeod R, Hillert EK, Cameron RT et al (2015) The role and therapeutic targeting of \u03b1-, \u03b2-and \u03b3-secretase in Alzheimer\u2019s disease. Futur Sci OA 1:3. https:\/\/doi.org\/10.4155\/fso.15.9","journal-title":"Futur Sci OA"},{"issue":"5","key":"3671_CR35","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1073\/pnas.0911829107","volume":"107","author":"C Balducci","year":"2010","unstructured":"Balducci C, Beeg M, Stravalaci M et al (2010) Synthetic amyloid-\u03b2 oligomers impair long-term memory independently of cellular prion protein. PNAS 107(5):2295\u20132300. https:\/\/doi.org\/10.1073\/pnas.0911829107","journal-title":"PNAS"},{"key":"3671_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fncel.2019.00339","volume":"13","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhao Y, Zhang L et al (2019) Cellular prion protein as a receptor of toxic amyloid-\u03b242 oligomers is important for Alzheimer\u2019s disease. Front Cell Neurosci 13:339. https:\/\/doi.org\/10.3389\/fncel.2019.00339","journal-title":"Front Cell Neurosci"},{"key":"3671_CR37","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y et al (2023) KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res 51:D587\u2013D592. https:\/\/doi.org\/10.1093\/nar\/gkac963","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3671_CR38","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/ncomms1341","volume":"2","author":"DB Freir","year":"2011","unstructured":"Freir DB, Nicoll AJ, Klyubin I et al (2011) Interaction between prion protein and toxic amyloid \u03b2 assemblies can be therapeutically targeted at multiple sites. Nat Commun 2(1):336. https:\/\/doi.org\/10.1038\/ncomms1341","journal-title":"Nat Commun"},{"key":"3671_CR39","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/nn1503","volume":"8","author":"E Snyder","year":"2005","unstructured":"Snyder E, Nong Y, Almeida C et al (2005) Regulation of NMDA receptor trafficking by amyloid-\u03b2. Nat Neurosci 8:1051\u20131058. https:\/\/doi.org\/10.1038\/nn1503","journal-title":"Nat Neurosci"},{"issue":"2","key":"3671_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1083\/jcb.200409127","volume":"169","author":"A Santuccione","year":"2005","unstructured":"Santuccione A, Sytnyk V, Leshchyns\u2019ka I et al (2005) Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol 169(2):341\u2013354. https:\/\/doi.org\/10.1083\/jcb.200409127","journal-title":"J Cell Biol"},{"issue":"9","key":"3671_CR41","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1212\/WNL.0000000000001903","volume":"85","author":"F Wang","year":"2015","unstructured":"Wang F, Gordon BA, Ryman DC et al (2015) Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology 85(9):790\u2013798. https:\/\/doi.org\/10.1212\/WNL.0000000000001903","journal-title":"Neurology"},{"issue":"13","key":"3671_CR42","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1093\/nar\/gkg563","volume":"31","author":"E Gasteiger","year":"2003","unstructured":"Gasteiger E, Gattiker A, Hoogland C et al (2003) ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 31(13):3784\u20133788. https:\/\/doi.org\/10.1093\/nar\/gkg563","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3671_CR43","doi-asserted-by":"publisher","first-page":"D20","DOI":"10.1093\/nar\/gkab1112","volume":"50","author":"EW Sayers","year":"2022","unstructured":"Sayers EW, Bolton EE, Brister JR et al (2022) Database resources of the national center for biotechnology information. Nucleic Acids Res 50(D1):D20\u2013D26. https:\/\/doi.org\/10.1093\/nar\/gkab1112","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3671_CR44","doi-asserted-by":"publisher","first-page":"a006247","DOI":"10.1101\/cshperspect.a006247","volume":"2","author":"EM Mandelkow","year":"2012","unstructured":"Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2(7):a006247. https:\/\/doi.org\/10.1101\/cshperspect.a006247","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3671_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14:399\u2013415. https:\/\/doi.org\/10.1038\/s41582-018-0013-z","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"3671_CR46","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1371\/journal.pbio.1000034","volume":"7","author":"MD Mukrasch","year":"2009","unstructured":"Mukrasch MD, Bibow S, Korukottu J et al (2009) Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol 7(2):e34. https:\/\/doi.org\/10.1371\/journal.pbio.1000034","journal-title":"PLoS Biol"},{"issue":"6","key":"3671_CR47","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1091\/mbc.9.6.1495","volume":"9","author":"S Illenberger","year":"2017","unstructured":"Illenberger S, Zheng-Fischh\u00f6fer Q, Preuss U et al (2017) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer\u2019s disease. Mol Biol Cell 9(6):1495\u20131512. https:\/\/doi.org\/10.1091\/mbc.9.6.1495","journal-title":"Mol Biol Cell"},{"issue":"19","key":"3671_CR48","doi-asserted-by":"publisher","first-page":"e2021461118","DOI":"10.1073\/pnas.2021461118","volume":"118","author":"MT Gyparaki","year":"2021","unstructured":"Gyparaki MT, Arab A, Sorokina EM et al (2021) Tau forms oligomeric complexes on microtubules that are distinct tau aggregates. Proc Natl Acad Sci U S A 118(19):e2021461118. https:\/\/doi.org\/10.1073\/pnas.2021461118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3671_CR49","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1096\/fj.08-123877","volume":"23","author":"P Gorlovoy","year":"2009","unstructured":"Gorlovoy P, Larionov S, Pham TTH et al (2009) Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J 23(8):2502\u20132513. https:\/\/doi.org\/10.1096\/fj.08-123877","journal-title":"FASEB J"},{"key":"3671_CR50","volume-title":"Computational modeling of drugs against Alzheimer\u2019s disease","year":"2018","unstructured":"Roy K (ed) (2018) Computational modeling of drugs against Alzheimer\u2019s disease. Springer, New York"},{"issue":"26","key":"3671_CR51","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1021\/jp104258d","volume":"114","author":"Y Zhou","year":"2010","unstructured":"Zhou Y, Wang S, Zhang Y (2010) Catalytic reaction mechanism of acetylcholinesterase determined by Born\u2212Oppenheimer ab initio QM\/MM molecular dynamics simulations. J Phys Chem B 114(26):8817\u20138825. https:\/\/doi.org\/10.1021\/jp104258d","journal-title":"J Phys Chem B"},{"issue":"7","key":"3671_CR52","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1021\/acs.jcim.9b01073","volume":"60","author":"MA Silva","year":"2020","unstructured":"Silva MA, Kiametis AS, Treptow W (2020) Donepezil inhibits acetylcholinesterase via multiple binding modes at room temperature. J Chem Inf Model 60(7):3463\u20133471. https:\/\/doi.org\/10.1021\/acs.jcim.9b01073","journal-title":"J Chem Inf Model"},{"issue":"8","key":"3671_CR53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/biom9080379","volume":"9","author":"B Svobodova","year":"2019","unstructured":"Svobodova B, Mezeiova E, Hepnarova V et al (2019) Exploring structure-activity relationship in tacrine-squaramide derivatives as potent cholinesterase inhibitors. Biomolecules 9(8):379. https:\/\/doi.org\/10.3390\/biom9080379","journal-title":"Biomolecules"},{"issue":"6","key":"3671_CR54","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/jnc.15379","volume":"158","author":"S Mak","year":"2021","unstructured":"Mak S, Li W, Fu H et al (2021) Promising tacrine\/huperzine A-based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders from relieving symptoms to modifying diseases through multitarget. J Neurochem 158(6):1381\u20131393. https:\/\/doi.org\/10.1111\/jnc.15379","journal-title":"J Neurochem"},{"key":"3671_CR55","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.ctim.2019.102294","volume":"49","author":"L Cassidy","year":"2020","unstructured":"Cassidy L, Fernandez F, Johnson JB et al (2020) Oxidative stress in Alzheimer\u2019s disease: a review on emergent natural polyphenolic therapeutics. Complement Ther Med 49:102294","journal-title":"Complement Ther Med"},{"key":"3671_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.biocel.2004.07.009","volume":"37","author":"EE Tuppo","year":"2005","unstructured":"Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer\u2019s disease. Int J Biochem Cell Biol 37:289\u2013305. https:\/\/doi.org\/10.1016\/j.biocel.2004.07.009","journal-title":"Int J Biochem Cell Biol"},{"key":"3671_CR57","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41398-021-01349-z","volume":"11","author":"NM Lyra e Silva","year":"2021","unstructured":"Lyra e Silva NM, Gon\u00e7alves RA, Pascoal TA et al (2021) Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer\u2019s disease. Transl Psychiatry 11:251. https:\/\/doi.org\/10.1038\/s41398-021-01349-z","journal-title":"Transl Psychiatry"},{"issue":"12","key":"3671_CR58","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/s0169-409x(02)00162-x","volume":"54","author":"AH Moore","year":"2002","unstructured":"Moore AH, O\u2019Banion MK (2002) Neuroinflammation and anti-inflammatory therapy for Alzheimer\u2019s disease. Adv Drug Deliv Rev 54(12):1627\u20131656. https:\/\/doi.org\/10.1016\/s0169-409x(02)00162-x","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3671_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.pu.13.050192.002243","volume":"13","author":"EB Larson","year":"1992","unstructured":"Larson EB, Kukull WA, Katzman RL (1992) Cognitive impairment: dementia and Alzheimer\u2019s disease. Annu Rev Public Health 13(1):431\u2013449. https:\/\/doi.org\/10.1146\/annurev.pu.13.050192.002243","journal-title":"Annu Rev Public Health"},{"key":"3671_CR60","doi-asserted-by":"publisher","first-page":"117957352090739","DOI":"10.1177\/1179573520907397","volume":"12","author":"KG Yiannopoulou","year":"2020","unstructured":"Yiannopoulou KG, Sokratis GP (2020) Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis 12:1179573520907397. https:\/\/doi.org\/10.1177\/1179573520907397","journal-title":"J Cent Nerv Syst Dis"},{"key":"3671_CR61","volume-title":"The molecular and cellular basis of neurodegenerative diseases","author":"MS Wolfe","year":"2018","unstructured":"Wolfe MS (2018) The molecular and cellular basis of neurodegenerative diseases. Academic Press"},{"issue":"4","key":"3671_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5688\/aj710478","volume":"71","author":"LK McCorry","year":"2007","unstructured":"McCorry LK (2007) Physiology of the autonomic nervous system. Am J Pharm Educ 71(4):78. https:\/\/doi.org\/10.5688\/aj710478","journal-title":"Am J Pharm Educ"},{"key":"3671_CR63","doi-asserted-by":"publisher","first-page":"705451","DOI":"10.1155\/2014\/705451","volume":"2014","author":"C Seniya","year":"2014","unstructured":"Seniya C, Khan GJ, Uchadia K (2014) Identification of potential herbal inhibitor of acetylcholinesterase associated Alzheimer\u2019s disorders using molecular docking and molecular dynamics simulation. Biochem Res Int 2014:705451. https:\/\/doi.org\/10.1155\/2014\/705451","journal-title":"Biochem Res Int"},{"key":"3671_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biosystems.2013.12.002","volume":"116","author":"P Ambure","year":"2014","unstructured":"Ambure P, Kar S, Roy K (2014) Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer\u2019s agents. Biosystems 116:10\u201320. https:\/\/doi.org\/10.1016\/j.biosystems.2013.12.002","journal-title":"Biosystems"},{"issue":"8","key":"3671_CR65","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2174\/1871527313666141023141545","volume":"13","author":"G Mushtaq","year":"2014","unstructured":"Mushtaq G, Greig NH, Khan JA et al (2014) Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer\u2019s disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 13(8):1432\u20131439. https:\/\/doi.org\/10.2174\/1871527313666141023141545","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"9","key":"3671_CR66","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","volume":"169","author":"SS Gill","year":"2009","unstructured":"Gill SS, Anderson GM, Fischer HD et al (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 169(9):867\u2013873. https:\/\/doi.org\/10.1001\/archinternmed.2009.43","journal-title":"Arch Intern Med"},{"key":"3671_CR67","volume-title":"Memory loss, Alzheimer's disease, and dementia: a practical guide for clinicians","author":"AE Budson","year":"2021","unstructured":"Budson AE, Solomon PR (2021). Memory loss, Alzheimer\u2019s disease, and dementia: a practical guide for clinicians. Elsevier Health Sciences"},{"key":"3671_CR68","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00115-004-1856-7","volume":"76","author":"M Singer","year":"2005","unstructured":"Singer M, Romero B, Koenig E et al (2005) Nightmares in patients with Alzheimer\u2019s disease caused by donepezil. Therapeutic effect depends on the time of intake. Nervenarzt 76:1127\u20131129. https:\/\/doi.org\/10.1007\/s00115-004-1856-7","journal-title":"Nervenarzt"},{"issue":"18","key":"3671_CR69","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/ijms20184331","volume":"20","author":"L Pinzi","year":"2019","unstructured":"Pinzi L, Rastelli G (2019) Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci 20(18):433. https:\/\/doi.org\/10.3390\/ijms20184331","journal-title":"Int J Mol Sci"},{"key":"3671_CR70","doi-asserted-by":"publisher","unstructured":"Phillips MA, Stewart MA, Woodling DL (2017) Has molecular docking ever brought us a medicine? Molecular Docking. InTech. https:\/\/doi.org\/10.5772\/intechopen.72898.","DOI":"10.5772\/intechopen.72898"},{"issue":"7","key":"3671_CR71","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2147\/DDDT.S41431","volume":"6","author":"L Ghezzi","year":"2013","unstructured":"Ghezzi L, Scarpini E, Galimberti D (2013) Disease-modifying drugs in Alzheimer\u2019s disease. Drug Des Devel Ther 6(7):1471\u20131479. https:\/\/doi.org\/10.2147\/DDDT.S41431","journal-title":"Drug Des Devel Ther"},{"key":"3671_CR72","doi-asserted-by":"publisher","first-page":"e12385","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G et al (2023) Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimer\u2019s Dement 9:e12385. https:\/\/doi.org\/10.1002\/trc2.12385","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"3671_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.neuropsych.20060152","volume":"33","author":"J Cummings","year":"2021","unstructured":"Cummings J (2021) Drug development for psychotropic, cognitive-enhancing, and disease-modifying treatments for Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci 33(1):3\u201313. https:\/\/doi.org\/10.1176\/appi.neuropsych.20060152","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"8","key":"3671_CR74","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","volume":"10","author":"W Chen","year":"2020","unstructured":"Chen W, Hu Y, Ju D (2020) Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B 10(8):1347\u20131359. https:\/\/doi.org\/10.1016\/j.apsb.2020.01.015","journal-title":"Acta Pharm Sin B"},{"issue":"Suppl 1","key":"3671_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2125.2004.01848.x","volume":"58","author":"S Jackson","year":"2004","unstructured":"Jackson S, Ham RJ, Wilkinson D et al (2004) The safety and tolerability of donepezil in patients with Alzheimer\u2019s disease. Br J Clin Pharmacol 58(Suppl 1):1\u20138. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.01848.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3671_CR76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/gps.2355","volume":"25","author":"JT Olin","year":"2010","unstructured":"Olin JT, Bhatnagar V, Reyes P et al (2010) Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer\u2019s disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 25(4):419\u2013426. https:\/\/doi.org\/10.1002\/gps.2355","journal-title":"Int J Geriatr Psychiatry"},{"key":"3671_CR77","doi-asserted-by":"publisher","first-page":"001747","DOI":"10.1002\/14651858.CD001747","volume":"3","author":"J Olin","year":"2002","unstructured":"Olin J, Schneider L (2002) Galantamine for Alzheimer\u2019s disease. The Cochrane Database Syst Rev 3:001747. https:\/\/doi.org\/10.1002\/14651858.CD001747","journal-title":"The Cochrane Database Syst Rev"},{"key":"3671_CR78","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/DNND.S228939","volume":"9","author":"J Rasmussen","year":"2019","unstructured":"Rasmussen J, Langerman H (2019) Alzheimer\u2019s disease\u2014why we need early diagnosis. Degener Neurol Neuromuscul Dis 9:123\u2013130. https:\/\/doi.org\/10.2147\/DNND.S228939","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"2","key":"3671_CR79","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1089\/hum.2016.017","volume":"27","author":"S Alves","year":"2016","unstructured":"Alves S, Fol R, Cartier N (2016) Gene therapy strategies for Alzheimer\u2019s disease: an overview. Hum Gene Ther 27(2):100\u2013107. https:\/\/doi.org\/10.1089\/hum.2016.017","journal-title":"Hum Gene Ther"},{"issue":"4","key":"3671_CR80","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/pharmaceutics10040269","volume":"10","author":"DM Teleanu","year":"2018","unstructured":"Teleanu DM, Chircov C, Grumezescu AM et al (2018) Blood-brain delivery methods using nanotechnology. Pharmaceutics 10(4):269. https:\/\/doi.org\/10.3390\/pharmaceutics10040269","journal-title":"Pharmaceutics"},{"key":"3671_CR81","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.copbio.2020.06.009","volume":"66","author":"CS Lee","year":"2020","unstructured":"Lee CS, Leong KW (2020) Advances in microphysiological blood-brain barrier (BBB) models towards drug delivery. Curr Opin Biotechnol 66:78\u201387. https:\/\/doi.org\/10.1016\/j.copbio.2020.06.009","journal-title":"Curr Opin Biotechnol"},{"key":"3671_CR82","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40005-021-00521-3","volume":"51","author":"R Duwa","year":"2021","unstructured":"Duwa R, Jeong J-H, Yook S (2021) Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson\u2019s disease. J Pharm Investig 51:465\u2013481. https:\/\/doi.org\/10.1007\/s40005-021-00521-3","journal-title":"J Pharm Investig"},{"key":"3671_CR83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/B978-0-444-63432-0.00003-7","volume":"133","author":"B Obermeier","year":"2016","unstructured":"Obermeier B, Verma A, Ransohoff RM (2016) The blood-brain barrier. Handb Clin Neurol 133:39\u201359. https:\/\/doi.org\/10.1016\/B978-0-444-63432-0.00003-7","journal-title":"Handb Clin Neurol"},{"key":"3671_CR84","doi-asserted-by":"publisher","unstructured":"Khanna AK, Farag E (2017) Blood\u2013brain barrier. In Essentials of neuroanesthesia 51\u201358. https:\/\/doi.org\/10.1016\/B978-0-12-805299-0.00003-8","DOI":"10.1016\/B978-0-12-805299-0.00003-8"},{"key":"3671_CR85","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1016\/j.biomaterials.2007.06.011","volume":"28","author":"A B\u00e9duneau","year":"2007","unstructured":"B\u00e9duneau A, Saulnier P, Benoit JP (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947\u20134967. https:\/\/doi.org\/10.1016\/j.biomaterials.2007.06.011","journal-title":"Biomaterials"},{"key":"3671_CR86","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","volume":"270","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Peng Z, Seven ES et al (2018) Crossing the blood-brain barrier with nanoparticles. J Control Release 270:290\u2013303. https:\/\/doi.org\/10.1016\/j.jconrel.2017.12.015","journal-title":"J Control Release"},{"key":"3671_CR87","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/molecules25081929","volume":"25","author":"SU Islam","year":"2020","unstructured":"Islam SU, Shehzad A, Ahmed MB et al (2020) Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules 25:1929. https:\/\/doi.org\/10.3390\/molecules25081929","journal-title":"Molecules"},{"key":"3671_CR88","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/molecules25081929","volume":"11","author":"LC Fonseca","year":"2021","unstructured":"Fonseca LC, Lopes JA, Vieira J et al (2021) Intranasal drug delivery for treatment of Alzheimer\u2019s disease. Drug Deliv Transl Res 11:411\u2013425. https:\/\/doi.org\/10.3390\/molecules25081929","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"3671_CR89","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1381612827666211122153946","volume":"28","author":"P Tripathi","year":"2022","unstructured":"Tripathi P, Shukla P, Beberich E (2022) Theranostic applications of nanomaterials in Alzheimer\u2019s disease: a multifunctional approach. Curr Pharm Des 28(2):116\u2013132. https:\/\/doi.org\/10.2174\/1381612827666211122153946","journal-title":"Curr Pharm Des"},{"key":"3671_CR90","doi-asserted-by":"publisher","first-page":"106549","DOI":"10.1016\/j.cct.2021.106549","volume":"109","author":"GL Gupta","year":"2021","unstructured":"Gupta GL, Samant NP (2021) Current druggable targets for therapeutic control of Alzheimer\u2019s disease. Contemp Clin Trials 109:106549. https:\/\/doi.org\/10.1016\/j.cct.2021.106549","journal-title":"Contemp Clin Trials"},{"issue":"43","key":"3671_CR91","doi-asserted-by":"publisher","first-page":"1701921","DOI":"10.1002\/smll.201701921","volume":"13","author":"YH Tsou","year":"2017","unstructured":"Tsou YH, Zhang XQ, Zhu H et al (2017) Drug delivery to the brain across the blood\u2013brain barrier using nanomaterials. Small 13(43):1701921. https:\/\/doi.org\/10.1002\/smll.201701921","journal-title":"Small"},{"issue":"3","key":"3671_CR92","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: an update. Bioeng Transl Med 4(3):e10143. https:\/\/doi.org\/10.1002\/btm2.10143","journal-title":"Bioeng Transl Med"},{"key":"3671_CR93","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A et al (2019) Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimer\u2019s Dement: Transl Res Clin Interv 5:272\u2013293. https:\/\/doi.org\/10.1016\/j.trci.2019.05.008","journal-title":"Alzheimer\u2019s Dement: Transl Res Clin Interv"},{"issue":"1","key":"3671_CR94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/molecules23010047","volume":"23","author":"M Vallet-Regi","year":"2017","unstructured":"Vallet-Regi M, Colilla M, Izquierdo-Barba I et al (2017) Mesoporous silica nanoparticles for drug delivery: current insights. Molecules 23(1):47. https:\/\/doi.org\/10.3390\/molecules23010047","journal-title":"Molecules"},{"issue":"8","key":"3671_CR95","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1177\/0271678X20985946","volume":"41","author":"EA Chowdhury","year":"2021","unstructured":"Chowdhury EA, Noorani B, Alqahtani F et al (2021) Understanding the brain uptake and permeability of small molecules through the BBB: a technical overview. J Cereb Blood Flow Metab 41(8):1797\u20131820. https:\/\/doi.org\/10.1177\/0271678X20985946","journal-title":"J Cereb Blood Flow Metab"},{"key":"3671_CR96","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2020.12.034","volume":"330","author":"V Gadekar","year":"2021","unstructured":"Gadekar V, Borade Y, Kannaujia S et al (2021) Nanomedicines accessible in the market for clinical interventions. J Control Release 330:372\u2013397. https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.034","journal-title":"J Control Release"},{"issue":"1","key":"3671_CR97","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/nnm-2018-0120","volume":"14","author":"F Farjadian","year":"2019","unstructured":"Farjadian F, Ghasemi A, Gohari O et al (2019) Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond) 14(1):93\u2013126. https:\/\/doi.org\/10.2217\/nnm-2018-0120","journal-title":"Nanomedicine (Lond)"},{"issue":"7","key":"3671_CR98","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/1389450120666191118123151","volume":"21","author":"G Altinoglu","year":"2020","unstructured":"Altinoglu G, Adali T (2020) Alzheimer\u2019s disease targeted nano-based drug delivery systems. Curr Drug Targets 21(7):628\u2013646. https:\/\/doi.org\/10.2174\/1389450120666191118123151","journal-title":"Curr Drug Targets"},{"key":"3671_CR99","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re TW et al (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537:50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"issue":"16","key":"3671_CR100","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules25163731","volume":"25","author":"A Zieli\u0144ska","year":"2020","unstructured":"Zieli\u0144ska A, Carreir\u00f3 F, Oliveira AM et al (2020) Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules 25(16):3731. https:\/\/doi.org\/10.3390\/molecules25163731","journal-title":"Molecules"},{"key":"3671_CR101","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm1239","volume":"11","author":"M Tuszynski","year":"2005","unstructured":"Tuszynski M, Thal L, Pay M et al (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551\u2013555. https:\/\/doi.org\/10.1038\/nm1239","journal-title":"Nat Med"},{"issue":"5","key":"3671_CR102","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.tibtech.2018.01.006","volume":"36","author":"M Zheng","year":"2018","unstructured":"Zheng M, Tao W, Zou Y et al (2018) Nanotechnology-based strategies for siRNA brain delivery for disease therapy. Trends Biotechnol 36(5):562\u2013575. https:\/\/doi.org\/10.1016\/j.tibtech.2018.01.006","journal-title":"Trends Biotechnol"},{"key":"3671_CR103","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrg2006","volume":"8","author":"D Kim","year":"2007","unstructured":"Kim D, Rossi J (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8:173\u2013184. https:\/\/doi.org\/10.1038\/nrg2006","journal-title":"Nat Rev Genet"},{"issue":"6","key":"3671_CR104","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/polym9060224","volume":"9","author":"S Lee","year":"2017","unstructured":"Lee S, Son SJ, Song SJ et al (2017) Polyamidoamine (PAMAM) dendrimers modified with cathepsin-B cleavable oligopeptides for enhanced gene delivery. Polymers 9(6):224. https:\/\/doi.org\/10.3390\/polym9060224","journal-title":"Polymers"},{"issue":"5","key":"3671_CR105","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.cell.2019.07.043","volume":"178","author":"J Suh","year":"2019","unstructured":"Suh J, Romano DM, Nitschke L et al (2019) Loss of ataxin-1 potentiates Alzheimer\u2019s pathogenesis by elevating cerebral BACE1 transcription. Cell 178(5):1159\u20131175. https:\/\/doi.org\/10.1016\/j.cell.2019.07.043","journal-title":"Cell"},{"issue":"21","key":"3671_CR106","doi-asserted-by":"publisher","first-page":"8173","DOI":"10.1002\/anie.201914751","volume":"59","author":"HS Min","year":"2020","unstructured":"Min HS, Kim HJ, Naito M et al (2020) Systemic brain delivery of antisense oligonucleotides across the blood\u2013brain barrier with a glucose-coated polymeric nanocarrier. Angew Chem Int Ed 59(21):8173\u20138180. https:\/\/doi.org\/10.1002\/anie.201914751","journal-title":"Angew Chem Int Ed"},{"issue":"20","key":"3671_CR107","doi-asserted-by":"publisher","first-page":"23328","DOI":"10.1021\/acsami.1c00257","volume":"13","author":"L Zhu","year":"2021","unstructured":"Zhu L, Xu L, Wu X et al (2021) Tau-targeted multifunctional nanoinhibitor for Alzheimer\u2019s disease. ACS Appl Mater Interfaces 13(20):23328\u201323338. https:\/\/doi.org\/10.1021\/acsami.1c00257","journal-title":"ACS Appl Mater Interfaces"},{"key":"3671_CR108","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.2147\/IJN.S183117","volume":"13","author":"C Ross","year":"2018","unstructured":"Ross C, Taylor M, Fullwood N et al (2018) Liposome delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomedicine 13:8507\u20138522. https:\/\/doi.org\/10.2147\/IJN.S183117","journal-title":"Int J Nanomedicine"},{"key":"3671_CR109","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.actbio.2019.01.065","volume":"87","author":"YC Kuo","year":"2019","unstructured":"Kuo YC, Chen CL, Rajesh R (2019) Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration. Acta Biomater 87:207\u2013222. https:\/\/doi.org\/10.1016\/j.actbio.2019.01.065","journal-title":"Acta Biomater"},{"issue":"23","key":"3671_CR110","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1016\/j.biomaterials.2011.04.020","volume":"32","author":"M Canovi","year":"2011","unstructured":"Canovi M, Markoutsa E, Lazar AN et al (2011) The binding affinity of anti-A\u03b21-42 MAb-decorated nanoliposomes to A\u03b21-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials 32(23):5489\u20135497. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.04.020","journal-title":"Biomaterials"},{"issue":"29","key":"3671_CR111","doi-asserted-by":"publisher","first-page":"8406","DOI":"10.1016\/j.biomaterials.2014.06.003","volume":"35","author":"AD Tagalakis","year":"2014","unstructured":"Tagalakis AD, Do Hyang DL, Bienemann AS et al (2014) Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. Biomaterials 35(29):8406\u20138415. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.06.003","journal-title":"Biomaterials"},{"issue":"5","key":"3671_CR112","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.nano.2012.11.004","volume":"9","author":"AN Lazar","year":"2013","unstructured":"Lazar AN, Mourtas S, Youssef I et al (2013) Curcumin-conjugated nanoliposomes with high affinity for A\u03b2 deposits: possible applications to Alzheimer disease. Nanomedicine 9(5):712\u2013721. https:\/\/doi.org\/10.1016\/j.nano.2012.11.004","journal-title":"Nanomedicine"},{"issue":"2","key":"3671_CR113","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1021\/cm0011559","volume":"13","author":"M Vallet-Regi","year":"2001","unstructured":"Vallet-Regi M, R\u00e1mila A, Del Real RP et al (2001) A new property of MCM-41: drug delivery system. Chem Mater 13(2):308\u2013311. https:\/\/doi.org\/10.1021\/cm0011559","journal-title":"Chem Mater"},{"issue":"1","key":"3671_CR114","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/cm402592t","volume":"26","author":"C Argyo","year":"2014","unstructured":"Argyo C, Weiss V, Br\u00e4uchle C et al (2014) Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem Mater 26(1):435\u2013451. https:\/\/doi.org\/10.1021\/cm402592t","journal-title":"Chem Mater"},{"issue":"3","key":"3671_CR115","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1021\/jz2013837","volume":"3","author":"YS Lin","year":"2012","unstructured":"Lin YS, Hurley KR, Haynes CL (2012) Critical considerations in the biomedical use of mesoporous silica nanoparticles. J Phys Chem Lett 3(3):364\u2013374. https:\/\/doi.org\/10.1021\/jz2013837","journal-title":"J Phys Chem Lett"},{"issue":"40","key":"3671_CR116","doi-asserted-by":"publisher","first-page":"7548","DOI":"10.1002\/anie.200604488","volume":"46","author":"M Vallet-Reg\u00ed","year":"2007","unstructured":"Vallet-Reg\u00ed M, Balas F, Arcos D (2007) Mesoporous materials for drug delivery. Angew Chem Int Ed Engl 46(40):7548\u20137558. https:\/\/doi.org\/10.1002\/anie.200604488","journal-title":"Angew Chem Int Ed Engl"},{"issue":"12","key":"3671_CR117","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/adma.201104763","volume":"24","author":"F Tang","year":"2012","unstructured":"Tang F, Li L, Chen D (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 24(12):1504\u20131534. https:\/\/doi.org\/10.1002\/adma.201104763","journal-title":"Adv Mater"},{"issue":"2","key":"3671_CR118","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1517\/17425247.2014.953051","volume":"12","author":"A Baeza","year":"2015","unstructured":"Baeza A, Colilla M, Vallet-Reg\u00ed M (2015) Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery. Expert Opin Drug Deliv 12(2):319\u2013337. https:\/\/doi.org\/10.1517\/17425247.2014.953051","journal-title":"Expert Opin Drug Deliv"},{"issue":"16","key":"3671_CR119","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/smll.201502119","volume":"12","author":"KS Butler","year":"2016","unstructured":"Butler KS, Durfee PN, Theron C et al (2016) Protocells: modular mesoporous silica nanoparticle-supported lipid bilayers for drug delivery. Small 12(16):2173\u20132185. https:\/\/doi.org\/10.1002\/smll.201502119","journal-title":"Small"},{"key":"3671_CR120","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/0022-3093(94)90708-0","volume":"179","author":"BC Bunker","year":"1994","unstructured":"Bunker BC (1994) Molecular mechanisms for corrosion of silica and silicate glasses. J Non-Cryst Solids 179:300\u2013308. https:\/\/doi.org\/10.1016\/0022-3093(94)90708-0","journal-title":"J Non-Cryst Solids"},{"key":"3671_CR121","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/0022-3093(94)90708-0","volume":"179","author":"BC Bunker","year":"1994","unstructured":"Bunker BC (1994) Molecular mechanisms for corrosion of silica and silicate glasses. J Non-Cryst Solids 179:300\u2013308. https:\/\/doi.org\/10.1016\/0022-3093(94)90708-0","journal-title":"J Non-Cryst Solids"},{"key":"3671_CR122","doi-asserted-by":"publisher","first-page":"147786","DOI":"10.1016\/j.brainres.2022.147786","volume":"1781","author":"SF Basharzad","year":"2022","unstructured":"Basharzad SF, Hamidi M, Maleki A et al (2022) Polysorbate-coated mesoporous silica nanoparticles as an efficient carrier for improved rivastigmine brain delivery. Brain Res 1781:147786. https:\/\/doi.org\/10.1016\/j.brainres.2022.147786","journal-title":"Brain Res"},{"issue":"3","key":"3671_CR123","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2174\/1570159X16666180918164623","volume":"17","author":"G Aliev","year":"2019","unstructured":"Aliev G, Ashraf GM, Tarasov VV et al (2019) Alzheimer\u2019s disease\u2014future therapy based on dendrimers. Curr Neuropharmacol 17(3):288\u2013294. https:\/\/doi.org\/10.2174\/1570159X16666180918164623","journal-title":"Curr Neuropharmacol"},{"issue":"14","key":"3671_CR124","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1523\/JNEUROSCI.4396-06.2007","volume":"27","author":"J Zhao","year":"2007","unstructured":"Zhao J, Fu Y, Yasvoina M et al (2007) \u03b2-Site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer\u2019s disease pathogenesis. J Neurosci 27(14):3639\u20133649. https:\/\/doi.org\/10.1523\/JNEUROSCI.4396-06.2007","journal-title":"J Neurosci"},{"key":"3671_CR125","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1021\/acs.bioconjchem.9b00505","volume":"30","author":"A Gothwal","year":"2019","unstructured":"Gothwal A, Kumar H, Nakhate KT et al (2019) Lactoferrin coupled lower generation PAMAM dendrimers for brain targeted delivery of memantine in aluminum-chloride-induced Alzheimer\u2019s disease in mice. Bioconjug Chem 30:2573\u20132583. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00505","journal-title":"Bioconjug Chem"},{"key":"3671_CR126","doi-asserted-by":"publisher","first-page":"1801586","DOI":"10.1002\/advs.201801586","volume":"6","author":"Y Lu","year":"2019","unstructured":"Lu Y, Guo Z, Zhang Y et al (2019) Microenvironment remodeling micelles for Alzheimer\u2019s disease therapy by early modulation of activated microglia. Adv Sci 6:1801586. https:\/\/doi.org\/10.1002\/advs.201801586","journal-title":"Adv Sci"},{"key":"3671_CR127","doi-asserted-by":"publisher","first-page":"119844","DOI":"10.1016\/j.biomaterials.2020.119844","volume":"238","author":"P Yang","year":"2020","unstructured":"Yang P, Sheng D, Guo Q et al (2020) Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer\u2019s disease. Biomaterials 238:119844. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119844","journal-title":"Biomaterials"},{"key":"3671_CR128","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3233\/JAD-2010-100462","volume":"22","author":"P Candela","year":"2010","unstructured":"Candela P, Gosselet F, Saint-Pol J et al (2010) Apical-to-basolateral transport of amyloid-\u03b2 peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimer\u2019s Dis 22:849\u2013859. https:\/\/doi.org\/10.3233\/JAD-2010-100462","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3671_CR129","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","volume":"11","author":"K Hou","year":"2020","unstructured":"Hou K, Zhao J, Wang H et al (2020) Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun 11:4790. https:\/\/doi.org\/10.1038\/s41467-020-18525-2","journal-title":"Nat Commun"},{"key":"3671_CR130","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1021\/acschemneuro.8b00622","volume":"10","author":"M Sanati","year":"2019","unstructured":"Sanati M, Khodagholi F, Aminyavari S et al (2019) Impact of gold nanoparticles on amyloid \u03b2-induced Alzheimer\u2019s disease in a rat animal model: involvement of STIM proteins. ACS Chem Neurosci 10:2299\u20132309. https:\/\/doi.org\/10.1021\/acschemneuro.8b00622","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"3671_CR131","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3390\/v14091905","volume":"14","author":"J He","year":"2022","unstructured":"He J, Yu L, Lin X et al (2022) Virus-like particles as nanocarriers for intracellular delivery of biomolecules and compounds. Viruses 14(9):1905. https:\/\/doi.org\/10.3390\/v14091905","journal-title":"Viruses"},{"issue":"7","key":"3671_CR132","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1517\/14712598.7.7.997","volume":"7","author":"T Ramqvist","year":"2007","unstructured":"Ramqvist T, Andreasson K, Dalianis T (2007) Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 7(7):997\u20131007. https:\/\/doi.org\/10.1517\/14712598.7.7.997","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"3671_CR133","doi-asserted-by":"publisher","first-page":"1700324","DOI":"10.1002\/biot.201700324","volume":"13","author":"X Ding","year":"2018","unstructured":"Ding X, Liu D, Booth G et al (2018) Virus-like particle engineering: from rational design to versatile applications. Biotechnol J 13(5):1700324. https:\/\/doi.org\/10.1002\/biot.201700324","journal-title":"Biotechnol J"},{"key":"3671_CR134","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ijbiomac.2022.03.203","volume":"208","author":"S Arora","year":"2022","unstructured":"Arora S, Kanekiyo T, Singh J (2022) Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer\u2019s disease pathology in transgenic mouse model. Int J Biol Macromol 208:901\u20139011. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.03.203","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"3671_CR135","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1073\/pnas.0409072102","volume":"102","author":"JC Dodart","year":"2005","unstructured":"Dodart JC, Marr RA, Koistinaho M et al (2005) Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 102(4):1211\u20131216. https:\/\/doi.org\/10.1073\/pnas.0409072102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3671_CR136","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1007\/s10853-017-0787-1","volume":"52","author":"JL Paris","year":"2017","unstructured":"Paris JL, Colilla M, Izquierdo-Barba I et al (2017) Tuning mesoporous silica dissolution in physiological environments: a review. J Mater Sci 52:8761\u20138771. https:\/\/doi.org\/10.1007\/s10853-017-0787-1","journal-title":"J Mater Sci"},{"issue":"20","key":"3671_CR137","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1021\/acs.langmuir.7b00332","volume":"33","author":"E Choi","year":"2017","unstructured":"Choi E, Kim S (2017) How can doxorubicin loading orchestrate in vitro degradation behaviors of mesoporous silica nanoparticles under a physiological condition? Langmuir 33(20):4974\u20134980. https:\/\/doi.org\/10.1021\/acs.langmuir.7b00332","journal-title":"Langmuir"},{"key":"3671_CR138","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3762\/bjnano.5.201","volume":"1905","author":"AK Barthel","year":"2014","unstructured":"Barthel AK, Dass M, Dr\u00f6ge M et al (2014) Imaging the intracellular degradation of biodegradable polymer nanoparticles. Beilstein J Nanotechnol. 1905:17. https:\/\/doi.org\/10.3762\/bjnano.5.201","journal-title":"Beilstein J Nanotechnol."},{"key":"3671_CR139","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s42247-021-00335-x","volume":"5","author":"V Chandrakala","year":"2022","unstructured":"Chandrakala V, Aruna V, Angajala G (2022) Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems. Emergent Mater. 5:1593\u20131615. https:\/\/doi.org\/10.1007\/s42247-021-00335-x","journal-title":"Emergent Mater."},{"key":"3671_CR140","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/ncomms1255","volume":"2","author":"T Cohen","year":"2011","unstructured":"Cohen T, Guo J, Hurtado D et al (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252. https:\/\/doi.org\/10.1038\/ncomms1255","journal-title":"Nat Commun"},{"issue":"1\u20133","key":"3671_CR141","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0014-5793(02)02228-7","volume":"512","author":"F Liu","year":"2002","unstructured":"Liu F, Zaidi T, Iqbal K et al (2002) Role of glycosylation in hyperphosphorylation of tau in Alzheimer\u2019s disease. FEBS Lett 512(1\u20133):101\u2013106. https:\/\/doi.org\/10.1016\/S0014-5793(02)02228-7","journal-title":"FEBS Lett"},{"key":"3671_CR142","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","volume":"3","author":"S Senapati","year":"2018","unstructured":"Senapati S, Mahanta AK, Kumar S et al (2018) Controlled drug delivery vehicles for cancer treatment and their performance. Sig Transduct Target Ther 3:7. https:\/\/doi.org\/10.1038\/s41392-017-0004-3","journal-title":"Sig Transduct Target Ther"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03671-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-023-03671-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03671-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T08:34:35Z","timestamp":1711528475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-023-03671-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3671"],"URL":"https:\/\/doi.org\/10.1007\/s12035-023-03671-7","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"19 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}}]}}